-
News
Scaccabarozzi: "The Yes is right about the referendum at least for health care". Why the No? The opinion of Cozza and Gaetti
A few days after the referendum, the president of Farmindustria expresses himself in favor of the reasons for the "yes" because "today in ...
Leggi » -
News
Federfarma and Snami: discussion on issues of common interest
The collaboration between family doctor and pharmacy in therapeutic adherence, the management of the paper memo and the effects on relationships…
Leggi » -
News
Shortcomings table, full speed ahead against wholesalers of (and for) convenience
Rome, November 29 - Stay faithful to the line. Which is that of the shared document signed by institutions and acronyms of the…
Leggi » -
News
Escape from hospitals, 40,000 specialists risk disappearing
Targeted hiring hiring and closed numbers Published 29/11/2016 – PAOLO RUSSO – LA STAMPA ITALIA After a…
Leggi » -
News
To Alberto Chiesi an honorary degree from the University of Parma
Alberto Chiesi received the honoris causa master's degree in Business Administration and Management from the University of Parma, for having "contributed in…
Leggi » -
News
Hon. Marisa Nicchi: Rule on Biotech drugs unjustified gift to the pharmaceutical industry
The measures contained in the Budget law on biotech drugs are a gift to the pharmaceutical industry and a damage to…
Leggi » -
News
The OECD promotes Italian healthcare, but raises the alarm about inequalities and antibiotic resistance
In the report "Health at a glance: Europe 2016" lights and shadows. Above average life expectancy and quality of care. They worry…
Leggi » -
News
Spesa farmaceutica, nel 2015 l’ospedaliera ‘batte’ la convenzionata è boom di farmaci e dispositivi innovativi
SIFO NE PARLA A MILANO: “PIU’ CONTROLLO, GARE MIGLIORI E LAVORARE DI PIU’ SU APPROPRIATEZZA” Roma, 23 novembre 2016 –…
Leggi » -
News
No to AIFA's Determination 458 on therapeutic equivalence
“Associazioni di cittadini e pazienti, professionisti sanitari e società scientifiche dicono NO alla Determina 458 di AIFA sulla equivalenza terapeutica”…
Leggi » -
News
Innovative drugs: more than 14 months pass between launch and access in Italy
14 mesi e mezzo. È questo il tempo che bisogna attendere affinché un nuovo farmaco sia disponibile sul mercato italiano,…
Leggi »